Publications by authors named "J D Hey"
Background: Adequate knowledge and awareness regarding diseases are essential for appropriate, high-quality healthcare. Female Genital Schistosomiasis (FGS) is a non-sexually transmitted gynaecological disease that is caused by the presence of Schistosoma haematobium eggs in the female genital tract and the resulting immune response that causes tissue damage. It is estimated to affect 56 million women, mostly in sub-Saharan Africa (SSA), where healthcare workers (HCWs) have limited awareness and knowledge of FGS.
View Article and Find Full Text PDFObjectives: The study compares three minimally invasive approaches for the retention of implant supported mandibular complete dentures, particularly focusing on patient satisfaction.
Background: The McGill Consensus Statement recommends restoration of the edentulous mandible with an overdenture retained on two implants. Alternatively, less invasive treatment concepts with shorter treatment times have been developed for critical cases.
Objectives: The aim of the present prospective study was to evaluate the colour stability of 3D-printed non-invasive restorations after 24 months in vivo.
Methods: The study included 29 patients, who received 3D-printed restorations made of a computer-aided design (CAD) / computer aided-manufacturing (CAM) hybrid material (n = 354). Restoration colour of 190 restorations was measured using a spectrophotometer.
Infection with Schistosoma haematobium causes urogenital disease associated with organ disfunction, bleeding, pain, and higher susceptibility to infections and cancer. Timely and accurate diagnosis is crucial for prompt and appropriate treatment as well as surveillance efforts, and the use of plasma biomarkers offers important advantages over parasitological examination of urine, including increased sensitivity and the possibility to use the same specimen for multiple investigations. The present study aims to evaluate the diagnostic performance of different plasma biomarkers in endemic populations from Burkina Faso, West Africa.
View Article and Find Full Text PDFArticle Synopsis
- The APOLLOE4 trial is a Phase 3 study evaluating the safety and efficacy of the oral drug ALZ-801 in patients with early Alzheimer's disease (AD) who possess the high-risk apolipoprotein E ε4/ε4 genotype.
- It enrolled 325 subjects aged 50-80, primarily with mild cognitive impairment, and aims to show a significant difference in cognitive function compared to a placebo over 78 weeks.
- Expected topline results in 2024 could provide insights into ALZ-801 as a potential first effective treatment for this high-risk group.